Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Gökbuget N, Kantarjian HM, Brüggemann M, Stein AS, Bargou RC, Dombret H, Fielding AK, Heffner L, Rigal-Huguet F, Litzow M, O'Brien S, Zugmaier G, Gao S, Nagorsen D, Forman SJ, Topp MS. Gökbuget N, et al. Among authors: bargou rc. Blood Adv. 2019 Oct 22;3(20):3033-3037. doi: 10.1182/bloodadvances.2019000457. Blood Adv. 2019. PMID: 31648325 Free PMC article.
Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA Consortium.
Lüke F, Haller F, Utpatel K, Krebs M, Meidenbauer N, Scheiter A, Spoerl S, Heudobler D, Sparrer D, Kaiser U, Keil F, Schubart C, Tögel L, Einhell S, Dietmaier W, Huss R, Dintner S, Sommer S, Jordan F, Goebeler ME, Metz M, Haake D, Scheytt M, Gerhard-Hartmann E, Maurus K, Brändlein S, Rosenwald A, Hartmann A, Märkl B, Einsele H, Mackensen A, Herr W, Kunzmann V, Bargou R, Beckmann MW, Pukrop T, Trepel M, Evert M, Claus R, Kerscher A. Lüke F, et al. Cancers (Basel). 2022 Oct 14;14(20):5040. doi: 10.3390/cancers14205040. Cancers (Basel). 2022. PMID: 36291825 Free PMC article.
The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany.
Krebs M, Haller F, Spörl S, Gerhard-Hartmann E, Utpatel K, Maurus K, Kunzmann V, Chatterjee M, Venkataramani V, Maatouk I, Bittrich M, Einwag T, Meidenbauer N, Tögel L, Hirsch D, Dietmaier W, Keil F, Scheiter A, Immel A, Heudobler D, Einhell S, Kaiser U, Sedlmeier AM, Maurer J, Schenkirsch G, Jordan F, Schmutz M, Dintner S, Rosenwald A, Hartmann A, Evert M, Märkl B, Bargou R, Mackensen A, Beckmann MW, Pukrop T, Herr W, Einsele H, Trepel M, Goebeler ME, Claus R, Kerscher A, Lüke F. Krebs M, et al. Eur J Cancer. 2024 Aug;207:114144. doi: 10.1016/j.ejca.2024.114144. Epub 2024 May 31. Eur J Cancer. 2024. PMID: 38852290 Free article.
7-Dehydrocholesterol is an endogenous suppressor of ferroptosis.
Freitas FP, Alborzinia H, Dos Santos AF, Nepachalovich P, Pedrera L, Zilka O, Inague A, Klein C, Aroua N, Kaushal K, Kast B, Lorenz SM, Kunz V, Nehring H, Xavier da Silva TN, Chen Z, Atici S, Doll SG, Schaefer EL, Ekpo I, Schmitz W, Horling A, Imming P, Miyamoto S, Wehman AM, Genaro-Mattos TC, Mirnics K, Kumar L, Klein-Seetharaman J, Meierjohann S, Weigand I, Kroiss M, Bornkamm GW, Gomes F, Netto LES, Sathian MB, Konrad DB, Covey DF, Michalke B, Bommert K, Bargou RC, Garcia-Saez A, Pratt DA, Fedorova M, Trumpp A, Conrad M, Friedmann Angeli JP. Freitas FP, et al. Among authors: bargou rc. Nature. 2024 Feb;626(7998):401-410. doi: 10.1038/s41586-023-06878-9. Epub 2024 Jan 31. Nature. 2024. PMID: 38297129
STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival.
Chatterjee M, Jain S, Stühmer T, Andrulis M, Ungethüm U, Kuban RJ, Lorentz H, Bommert K, Topp M, Krämer D, Müller-Hermelink HK, Einsele H, Greiner A, Bargou RC. Chatterjee M, et al. Among authors: bargou rc. Blood. 2007 Jan 15;109(2):720-8. doi: 10.1182/blood-2006-05-024372. Epub 2006 Sep 26. Blood. 2007. PMID: 17003370 Free article.
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P. Bargou R, et al. Science. 2008 Aug 15;321(5891):974-7. doi: 10.1126/science.1158545. Science. 2008. PMID: 18703743 Clinical Trial.
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, Vollmuth C, Falk K, Glasmacher A, Maeder U, Einsele H, Bargou RC. Knop S, et al. Among authors: bargou rc. Blood. 2009 Apr 30;113(18):4137-43. doi: 10.1182/blood-2008-10-184135. Epub 2009 Jan 30. Blood. 2009. PMID: 19182205 Free article. Clinical Trial.
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC. Topp MS, et al. Among authors: bargou rc. J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16. J Clin Oncol. 2011. PMID: 21576633 Clinical Trial.
147 results